×
About 55 results

ALLMedicine™ Acute Myeloblastic Leukemia Center

Research & Reviews  22 results

Safety of FLT3 inhibitors in patients with acute myeloid leukemia.
https://doi.org/10.1080/17474086.2021.1969911
Expert Review of Hematology; Cerchione C, Peleteiro Raíndo A et. al.

Aug 24th, 2021 - Introduction: Acute myeloblastic leukemia (AML) is the most frequent type of acute leukemia in adults with an incidence of 4.2 cases per 100,000 inhabitants and poor 5-year survival. Patients with mutations in the FMS-like tyrosine kinase 3 (FLT3)...

Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and R...
https://doi.org/10.1097/MPH.0000000000002225
Journal of Pediatric Hematology/oncology; Aylan Gelen S, Sarper N et. al.

Jun 1st, 2021 - Indications of leukapheresis (LPh) and the prophylactic use of rasburicase in tumor lysis syndrome (TLS) of patients with acute leukemia with hyperleukocytosis are not clear. In this retrospective single-center pediatric study, the outcomes of pat...

Biomarkers involved in evaluation of platelets function in South-Eastern Romanian patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137019
Medicine Matei E, Aschie M et. al.

May 21st, 2021 - At present, various researches presented how subtypes of hematological malignancies are related to stages of the immune response, because the activated immune system represents a promising form in cancer treatment. This study explores the relation...

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide ...
https://doi.org/10.1016/j.leukres.2020.106490
Leukemia Research; Djamai H, Berrou J et. al.

Dec 30th, 2020 - Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kin...

Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a p...
https://doi.org/10.1007/s10006-020-00851-w
Oral and Maxillofacial Surgery; Bumm CV, Folwaczny M et. al.

May 21st, 2020 - Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to cases of MRONJ in ...

see more →